<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01610687</url>
  </required_header>
  <id_info>
    <org_study_id>GWMS0001 EXT</org_study_id>
    <nct_id>NCT01610687</nct_id>
  </id_info>
  <brief_title>A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis</brief_title>
  <official_title>A Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GW Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GW Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An extension study to evaluate the long-term safety, tolerability and efficacy of GW-1000-02
      treatment in multiple sclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who participated in the placebo controlled phase of this study and opted to continue
      receiving open label GW-1000-02 entered the follow-on extension of the study and completed
      symptom assessments to determine whether they were continuing to receive clinical benefit
      from GW-1000-02.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2001</start_date>
  <completion_date type="Actual">February 2005</completion_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events as a Measure of Patient Safety</measure>
    <time_frame>up to1206 days</time_frame>
    <description>The number of patients who experienced an adverse event during the course of this extension study is presented</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Sprays of Study Medication Taken During the Last 6 Days of Treatment</measure>
    <time_frame>up to 1206 days</time_frame>
    <description>A categorical summary was produced of the mean number of sprays per day during the last six days of treatment, and the mean number of sprays was rounded to the nearest whole number for categorisation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Intoxication 100 mm Visual Analogue Scale Scores at Week 18.</measure>
    <time_frame>18 weeks</time_frame>
    <description>Intoxication levels were recorded on a Visual Analogue Scale, where 0 equals 'no intoxication' and 10 equals 'extreme intoxication'. A decrease in score indicates an improvement in intoxication levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Assessed Global Severity Score at Week 18</measure>
    <time_frame>week 18</time_frame>
    <description>The investigator rated the global severity of the subject's primary condition since entry into the study using a five-point verbal rating scale-5: 1=much worse, 2=worse, 3=no change, 4=better, 5=much better. The number of patients which were considered better or much better (scores 4 and 5) at week 18 of the study better is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Mean Pain 100 mm Visual Analogue Scale Score at Week 18</measure>
    <time_frame>week 18</time_frame>
    <description>A clinical assessment of pain was made at each study visit using a 100 mm Visual Analogue Scale, where 0 = no pain and 100 = worst possible pain. A decrease in score indicates an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Mean Spasticity 100 mm Visual Analogue Scale Score at Week 18</measure>
    <time_frame>week 18</time_frame>
    <description>A clinical assessment of spasticity was made at each study visit using a 100 mm Visual Analogue Scale, where 0 = no spasticity and 100 = worst possible spasticity. A decrease in score indicates an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Mean Tremor 100 mm Visual Analogue Scale Score at Week 18</measure>
    <time_frame>week 18</time_frame>
    <description>A clinical assessment of tremor was made at each study visit using a 100 mm Visual Analogue Scale, where 0 = no tremor and 100 = worst possible tremor. A decrease in score indicates an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Mean Bladder Problems 100 mm Visual Analogue Scale Score at Week 18</measure>
    <time_frame>18 weeks</time_frame>
    <description>A clinical assessment of bladder problems was made at each study visit using a 100 mm Visual Analogue Scale, where 0 = no bladder problems and 100 = worst possible bladder problems. A decrease in score indicates an improvement.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Spasticity</condition>
  <arm_group>
    <arm_group_label>GW-1000-02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW-1000-02</intervention_name>
    <description>Contained THC and CBD as extract of Cannabis sativa L. Each 100 μl actuation delivered a dose containing 2.7 mg THC and 2.5mg CBD. The maximum permitted dose was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.</description>
    <arm_group_label>GW-1000-02</arm_group_label>
    <other_name>Sativex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged at least 18 years.

          -  Multiple Sclerosis of any type.

          -  Stable Multiple Sclerosis symptomatology during the four weeks before study entry.

          -  Symptoms of the required severity (&gt;50 mm on a 100 mm Visual Analogue Scale severity
             scale) in least one of the specified impairment categories; spasticity, muscle spasms,
             disturbed bladder control, neuropathic pain, limb tremor.

          -  A stable medication regime during the four weeks before study entry.

          -  Willing to abstain from cannabis or cannabinoids for at least seven days before study
             entry, and during the study.

          -  Agreed either to use effective contraception during the study and for three months
             thereafter, or had been surgically sterilised or, if female, were post-menopausal.

          -  Clinically acceptable laboratory results for pre-study screening.

          -  Willing and able to undertake and comply with all study requirements.

          -  Willing and able to read, consider and understand the subject information and consent
             form and give written informed consent. Subjects unable to read or to sign the
             document procedures were treated as detailed in the Declaration of Helsinki.

          -  Willing for their general practitioner, and consultant if appropriate, to be informed
             of study participation.

          -  Willing for their name to be notified to Home Office for participation in the study.

        Exclusion Criteria:

          -  Known or strongly suspected to be abusing drugs, including alcohol.

          -  Not prepared to abstain from cannabis or cannabinoids during the study.

          -  Current or past addiction to cannabis.

          -  Known or suspected to have had an adverse reaction to cannabinoids causing psychosis
             or other severe psychiatric illness.

          -  History of any type of schizophrenia, any other psychotic illness, or other
             significant psychiatric illness or personality disorder other than depression
             associated with chronic illness.

          -  Received any drug containing levodopa (Sinemet®, Sinemet plus®, Levodopa®, L-dopa®,
             Madopar®, Benserazide®).

          -  Serious cardiovascular disorder including angina, uncontrolled hypertension, or an
             uncontrolled symptomatic cardiac arrhythmia.

          -  Significant renal or hepatic impairment as shown in medical history or indicated by
             laboratory results.

          -  History of epilepsy.

          -  Terminal illness or other condition in which placebo medication would be
             inappropriate.

          -  Pregnant, lactating or at risk of pregnancy.

          -  Participated in any other clinical research study during the 12 weeks before study
             entry.

          -  Planned hospital admission between study entry and Visit 6.

          -  Planned travel outside the UK between study entry and Visit 6.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derick Wade, FRCP MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rivermead Rehabilitation Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rivermead Rehabilitation Centre</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler. 2006 Oct;12(5):639-45.</citation>
    <PMID>17086911</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2012</study_first_submitted>
  <study_first_submitted_qc>June 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2012</study_first_posted>
  <results_first_submitted>July 11, 2012</results_first_submitted>
  <results_first_submitted_qc>July 11, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 17, 2012</results_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GW-1000-02</title>
          <description>GW-1000-02 contains Δ tetrahydrocannabinol, 27 mg/ml and cannabidiol, 25 mg/ml as extract of Cannabis sativa L. Subjects received study medication delivered in 100 μl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved out of area</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Symptom control without study medication</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to make journey</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Cannabis affecting job</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Felt more alter without study medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GW-1000-02</title>
          <description>Active treatment</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="137"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.69" spread="9.531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Events as a Measure of Patient Safety</title>
        <description>The number of patients who experienced an adverse event during the course of this extension study is presented</description>
        <time_frame>up to1206 days</time_frame>
        <population>All subjects who took at least one dose of study medication after the end of the Part B open-label phase of the acute study, and yielded on-treatment efficacy data was classed as the efficacy and safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GW-1000-02</title>
            <description>Contains THC (27 mg/ml) and CBD (25 mg/ml). Subjects received study medication delivered in 100 μl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events as a Measure of Patient Safety</title>
          <description>The number of patients who experienced an adverse event during the course of this extension study is presented</description>
          <population>All subjects who took at least one dose of study medication after the end of the Part B open-label phase of the acute study, and yielded on-treatment efficacy data was classed as the efficacy and safety population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Sprays of Study Medication Taken During the Last 6 Days of Treatment</title>
        <description>A categorical summary was produced of the mean number of sprays per day during the last six days of treatment, and the mean number of sprays was rounded to the nearest whole number for categorisation.</description>
        <time_frame>up to 1206 days</time_frame>
        <population>All subjects who took at least one dose of study medication after the end of the Part B open-label phase of the acute study, and yielded on-treatment efficacy data was classed as the efficacy and safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GW-1000-02</title>
            <description>Contains THC (27 mg/ml) and CBD (25 mg/ml). Subjects received study medication delivered in 100 μl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Sprays of Study Medication Taken During the Last 6 Days of Treatment</title>
          <description>A categorical summary was produced of the mean number of sprays per day during the last six days of treatment, and the mean number of sprays was rounded to the nearest whole number for categorisation.</description>
          <population>All subjects who took at least one dose of study medication after the end of the Part B open-label phase of the acute study, and yielded on-treatment efficacy data was classed as the efficacy and safety population.</population>
          <units>sprays of study medication</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.09" spread="7.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Intoxication 100 mm Visual Analogue Scale Scores at Week 18.</title>
        <description>Intoxication levels were recorded on a Visual Analogue Scale, where 0 equals 'no intoxication' and 10 equals 'extreme intoxication'. A decrease in score indicates an improvement in intoxication levels.</description>
        <time_frame>18 weeks</time_frame>
        <population>All subjects who took at least one dose of study medication after the end of the Part B open-label phase of the acute study, and yielded on-treatment efficacy data was classed as the efficacy and safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GW-1000-02</title>
            <description>Contains THC (27 mg/ml) and CBD (25 mg/ml). Subjects received study medication delivered in 100 μl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Intoxication 100 mm Visual Analogue Scale Scores at Week 18.</title>
          <description>Intoxication levels were recorded on a Visual Analogue Scale, where 0 equals 'no intoxication' and 10 equals 'extreme intoxication'. A decrease in score indicates an improvement in intoxication levels.</description>
          <population>All subjects who took at least one dose of study medication after the end of the Part B open-label phase of the acute study, and yielded on-treatment efficacy data was classed as the efficacy and safety population.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.65" spread="14.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Assessed Global Severity Score at Week 18</title>
        <description>The investigator rated the global severity of the subject's primary condition since entry into the study using a five-point verbal rating scale-5: 1=much worse, 2=worse, 3=no change, 4=better, 5=much better. The number of patients which were considered better or much better (scores 4 and 5) at week 18 of the study better is presented.</description>
        <time_frame>week 18</time_frame>
        <population>All subjects who took at least one dose of study medication after the end of the Part B open-label phase of the acute study, and yielded on-treatment efficacy data was classed as the efficacy and safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GW-1000-02</title>
            <description>Contains THC (27 mg/ml) and CBD (25 mg/ml). Subjects received study medication delivered in 100 μl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Assessed Global Severity Score at Week 18</title>
          <description>The investigator rated the global severity of the subject's primary condition since entry into the study using a five-point verbal rating scale-5: 1=much worse, 2=worse, 3=no change, 4=better, 5=much better. The number of patients which were considered better or much better (scores 4 and 5) at week 18 of the study better is presented.</description>
          <population>All subjects who took at least one dose of study medication after the end of the Part B open-label phase of the acute study, and yielded on-treatment efficacy data was classed as the efficacy and safety population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Mean Pain 100 mm Visual Analogue Scale Score at Week 18</title>
        <description>A clinical assessment of pain was made at each study visit using a 100 mm Visual Analogue Scale, where 0 = no pain and 100 = worst possible pain. A decrease in score indicates an improvement.</description>
        <time_frame>week 18</time_frame>
        <population>All subjects who took at least one dose of study medication after the end of the Part B open-label phase of the acute study, and yielded on-treatment efficacy data was classed as the efficacy and safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GW-1000-02</title>
            <description>Contains THC (27 mg/ml) and CBD (25 mg/ml). Subjects received study medication delivered in 100 μl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Mean Pain 100 mm Visual Analogue Scale Score at Week 18</title>
          <description>A clinical assessment of pain was made at each study visit using a 100 mm Visual Analogue Scale, where 0 = no pain and 100 = worst possible pain. A decrease in score indicates an improvement.</description>
          <population>All subjects who took at least one dose of study medication after the end of the Part B open-label phase of the acute study, and yielded on-treatment efficacy data was classed as the efficacy and safety population.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.34" spread="27.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Mean Spasticity 100 mm Visual Analogue Scale Score at Week 18</title>
        <description>A clinical assessment of spasticity was made at each study visit using a 100 mm Visual Analogue Scale, where 0 = no spasticity and 100 = worst possible spasticity. A decrease in score indicates an improvement.</description>
        <time_frame>week 18</time_frame>
        <population>All subjects who took at least one dose of study medication after the end of the Part B open-label phase of the acute study, and yielded on-treatment efficacy data was classed as the efficacy and safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GW-1000-02</title>
            <description>Contains THC (27 mg/ml) and CBD (25 mg/ml). Subjects received study medication delivered in 100 μl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Mean Spasticity 100 mm Visual Analogue Scale Score at Week 18</title>
          <description>A clinical assessment of spasticity was made at each study visit using a 100 mm Visual Analogue Scale, where 0 = no spasticity and 100 = worst possible spasticity. A decrease in score indicates an improvement.</description>
          <population>All subjects who took at least one dose of study medication after the end of the Part B open-label phase of the acute study, and yielded on-treatment efficacy data was classed as the efficacy and safety population.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.81" spread="24.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Mean Tremor 100 mm Visual Analogue Scale Score at Week 18</title>
        <description>A clinical assessment of tremor was made at each study visit using a 100 mm Visual Analogue Scale, where 0 = no tremor and 100 = worst possible tremor. A decrease in score indicates an improvement.</description>
        <time_frame>week 18</time_frame>
        <population>All subjects who took at least one dose of study medication after the end of the Part B open-label phase of the acute study, and yielded on-treatment efficacy data was classed as the efficacy and safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GW-1000-02</title>
            <description>Contains THC (27 mg/ml) and CBD (25 mg/ml). Subjects received study medication delivered in 100 μl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Mean Tremor 100 mm Visual Analogue Scale Score at Week 18</title>
          <description>A clinical assessment of tremor was made at each study visit using a 100 mm Visual Analogue Scale, where 0 = no tremor and 100 = worst possible tremor. A decrease in score indicates an improvement.</description>
          <population>All subjects who took at least one dose of study medication after the end of the Part B open-label phase of the acute study, and yielded on-treatment efficacy data was classed as the efficacy and safety population.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.23" spread="23.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Mean Bladder Problems 100 mm Visual Analogue Scale Score at Week 18</title>
        <description>A clinical assessment of bladder problems was made at each study visit using a 100 mm Visual Analogue Scale, where 0 = no bladder problems and 100 = worst possible bladder problems. A decrease in score indicates an improvement.</description>
        <time_frame>18 weeks</time_frame>
        <population>All subjects who took at least one dose of study medication after the end of the Part B open-label phase of the acute study, and yielded on-treatment efficacy data was classed as the efficacy and safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GW-1000-02</title>
            <description>Contains THC (27 mg/ml) and CBD (25 mg/ml). Subjects received study medication delivered in 100 μl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Mean Bladder Problems 100 mm Visual Analogue Scale Score at Week 18</title>
          <description>A clinical assessment of bladder problems was made at each study visit using a 100 mm Visual Analogue Scale, where 0 = no bladder problems and 100 = worst possible bladder problems. A decrease in score indicates an improvement.</description>
          <population>All subjects who took at least one dose of study medication after the end of the Part B open-label phase of the acute study, and yielded on-treatment efficacy data was classed as the efficacy and safety population.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.60" spread="25.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events occurring from during the extension study (up to 1049 days) were collected. All deaths and serious adverse events occurring within 28 days of the final dose of study medication were also collected.</time_frame>
      <desc>All adverse events occurring during the study were reported on the running logs at the back of the study case report form.</desc>
      <group_list>
        <group group_id="E1">
          <title>GW-1000-02</title>
          <description>Contains THC (27 mg/ml) and CBD (25 mg/ml). Subjects received study medication delivered in 100 μl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 5.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Diarrhoea NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary Cirrhosis Primary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection Not Otherwise Specified (NOS)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pneumonia NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Bone infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Lower Limb Fracture NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Muscle Weakness NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Breast Cancer NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Lung Cancer Stage Unspecified (excl metastatic tumours to lung)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple Sclerosis Relapse</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Balance Impaired NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Convulsions NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Panic Attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Psychotic Disorder NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3.6</frequency_threshold>
        <default_vocab>MedDRA 5.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ORAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>DIARRHOEA NOS</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>VOMITING NOS</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>GLOSSODYNIA</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>ORAL MUCOSAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>ORAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>MOUTH ULCERATION</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>LOOSE STOOLS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>TOOTH DISCOLOURATION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE IRRITATION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>FEELING ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>URINARY TRACT INFECTION NOS</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION NOS</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>TOOTH CARIES NOS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>BACTERIAL INFECTION NOS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>BLADDER INFECTION NOS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>VAGINAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION NOS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PAIN IN LIMB</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>MUSCLE WEAKNESS NOS</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>JOINT SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>HEADACHE NOS</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>BALANCE IMPAIRED NOS</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>MULTIPLE SCLEROSIS AGGRAVATED</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>MULTIPLE SCLEROSIS RELAPSE</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>DISTURBANCE IN ATTENTION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>MEMORY IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>SHORT-TERM MEMORY LOSS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>DEPRESSED MOOD</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>DISORIENTATION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>THROAT IRRITATION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GW will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications, for example manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mr Richard Potts, Clinical Operations Director</name_or_title>
      <organization>GW Pharma Ltd.</organization>
      <phone>0044 1223 266800</phone>
      <email>rp@gwpharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

